Wird geladen...
Using PARP Inhibitors in the Treatment of Patients with Ovarian Cancer
Use of Poly(ADP-Ribose) Polymerase (PARP) inhibitors has greatly increased over the past five years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and...
Gespeichert in:
| Veröffentlicht in: | Curr Treat Options Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8240125/ https://ncbi.nlm.nih.gov/pubmed/30535808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0572-7 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|